journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/28089655/statins-and-primary-prevention-of-venous-thromboembolism-a-systematic-review-and-meta-analysis
#1
Setor K Kunutsor, Samuel Seidu, Kamlesh Khunti
BACKGROUND: Statins have been suggested to have a protective effect on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain. We sought to evaluate the extent to which statins are associated with first venous thromboembolism events. METHODS: We did a systematic review and meta-analysis of observational cohort studies and randomised controlled trials (RCTs). Relevant studies that reported associations between statins and first venous thromboembolism outcomes were identified from MEDLINE, Embase, Web of Science, Cochrane Library, and a manual search of bibliographies for studies published up until July 18, 2016, and from email correspondence with investigators...
January 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28089654/statins-in-prevention-of-venous-thromboembolism
#2
Anetta Undas
No abstract text is available yet for this article.
January 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28089238/ruxolitinib-for-symptom-control-in-patients-with-chronic-lymphocytic-leukaemia-a-single-group-phase-2-trial
#3
Preetesh Jain, Michael Keating, Sarah Renner, Charles Cleeland, Huang Xuelin, Graciela Nogueras Gonzalez, David Harris, Ping Li, Zhiming Liu, Ivo Veletic, Uri Rozovski, Nitin Jain, Phillip Thompson, Prithviraj Bose, Courtney DiNardo, Alessandra Ferrajoli, Susan O'Brien, Jan Burger, William Wierda, Srdan Verstovsek, Hagop Kantarjian, Zeev Estrov
BACKGROUND: Disease-related symptoms impair the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic therapy. Available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL. We did a phase 2 trial of ruxolitinib to test this hypothesis...
January 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28089237/cll-when-the-target-of-treatment-is-disease-related-symptoms
#4
Stefano Molica, Emili Montserrat
No abstract text is available yet for this article.
January 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28041583/combination-of-ofatumumab-and-reduced-dose-chop-for-diffuse-large-b-cell-lymphomas-in-patients-aged-80-years-or-older-an-open-label-multicentre-single-arm-phase-2-trial-from-the-lysa-group
#5
Frédéric Peyrade, Serge Bologna, Vincent Delwail, Jean François Emile, Laurent Pascal, Christophe Fermé, Jean-Marc Schiano, Bertrand Coiffier, Bernadette Corront, Hassan Farhat, Christophe Fruchart, Herve Ghesquieres, Margaret Macro, Hervé Tilly, Bachra Choufi, Richard Delarue, Olivier Fitoussi, Jean Gabarre, Corinne Haioun, Fabrice Jardin
BACKGROUND: In 2011 we reported a rituximab plus miniCHOP (reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone) combination for patients older than 80 years with diffuse large B-cell lymphoma (DLBCL). The 2-year overall survival was 59% (95% CI 49-67) with an excess of early toxicity. To improve those results we tested the same chemotherapy protocol in combination with ofatumumab and a pre-phase treatment. METHODS: For this open-label, multicentre, single-group, phase 2 trial, we recruited patients older than 80 years with untreated histologically-proven CD20-positive DLBCL, Ann Arbor stage I to IV, from 41 academic and hospital centres in France and Belgium...
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28041582/58th-american-society-of-hematology-annual-meeting
#6
Lan-Lan Smith
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28041581/clinical-trial-reporting-an-evolving-process
#7
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27964867/consolidation-anti-cd22-fractionated-radioimmunotherapy-with-90-y-epratuzumab-tetraxetan-following-r-chop-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-prospective-single-group-phase-2-trial
#8
Françoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, Loïc Campion, Anne Moreau, Isabelle Soubeyran, Steven Le Gouill, Olivier Tournilhac, Etienne Daguindau, Henry Jardel, Nadine Morineau, Krimo Bouabdallah, Emmanuel Gyan, Marie-Pierre Moles, Remy Gressin, Christian Berthou, Sophie Sadot, Philippe Moreau, Bénédicte Deau, Caroline Bodet-Milin, Anne-Laure Cazeau, Etienne Garin, Pierre-Yves Salaun, Jean-Philippe Vuillez, Valérie Gouilleux-Gruart, Jacques Barbet, William A Wegener, David M Goldenberg, Thierry Lamy, Pierre Soubeyran
BACKGROUND: Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma. METHODS: We did a prospective, single-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals...
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27964866/radioimmunotherapy-of-lymphoma-an-underestimated-therapy-option
#9
Karin Hohloch
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27927586/rituximab-bendamustine-and-low-dose-cytarabine-as-induction-therapy-in-elderly-patients-with-mantle-cell-lymphoma-a-multicentre-phase-2-trial-from-fondazione-italiana-linfomi
#10
Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero, Andrea Evangelista, Michele Spina, Annalia Molinari, Luigi Rigacci, Monica Tani, Alice Di Rocco, Graziella Pinotti, Alberto Fabbri, Renato Zambello, Silvia Finotto, Manuel Gotti, Angelo M Carella, Flavia Salvi, Stefano A Pileri, Marco Ladetto, Giovannino Ciccone, Gianluca Gaidano, Marco Ruggeri, Maurizio Martelli, Umberto Vitolo
BACKGROUND: The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymphoma, but its use was restricted by high haematological toxicity. We aimed to assess the efficacy and safety of an R-BAC regimen with low-dose cytarabine (RBAC500). METHODS: In this multicentre, phase 2 trial, we recruited previously untreated patients with an established histological diagnosis of mantle cell lymphoma from 29 Fondazione Italiana Linfomi centres in Italy...
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27927585/bendamustine-rituximab-in-mantle-cell-lymphoma
#11
Andrew Lipsky, Peter Martin
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27916632/a-statistician-s-perspective-on-a-long-time-to-publish
#12
Amylou C Dueck
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27916631/a-clinician-s-perspective-on-a-long-time-to-publish
#13
Frederic Peyrade
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27916630/time-to-publish-challenging-the-performance-of-cooperative-group-lymphoma-trials
#14
Massimo Federico, Judith Trotman, Martin Dreyling
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27914971/once-weekly-ofatumumab-in-untreated-or-relapsed-waldenstr%C3%A3-m-s-macroglobulinaemia-an-open-label-single-arm-phase-2-study
#15
Richard R Furman, Herbert A Eradat, Christine G DiRienzo, Craig C Hofmeister, Suzanne R Hayman, John P Leonard, Morton Coleman, Ranjana Advani, Asher Chanan-Khan, Julie Switzky, Qiming M Liao, Damini Shah, Roxanne C Jewell, Steen Lisby, Thomas S Lin
BACKGROUND: The development of more effective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenström's macroglobulinaemia. METHODS: We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA. Patients aged at least 18 years who were diagnosed with untreated or relapsed Waldenström's macroglobulinaemia and required treatment, received up to three cycles of weekly ofatumumab for 5 weeks...
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27914970/ofatumumab-another-way-to-target-cd20-in-waldenstr%C3%A3-m-s-macroglobulinaemia
#16
Christian Buske
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27890073/switching-to-nilotinib-versus-imatinib-dose-escalation-in-patients-with-chronic-myeloid-leukaemia-in-chronic-phase-with-suboptimal-response-to-imatinib-lasor-a-randomised-open-label-trial
#17
Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, Jose Luis Lopez, Eduardo Bullorsky, Sandip Shah, Xiaojun Huang, K Govind Babu, Kudrat Abdulkadyrov, José Salvador Rodrigues de Oliveira, Zhi-Xiang Shen, Tomasz Sacha, Israel Bendit, Zhizhou Liang, Tina Owugah, Tomasz Szczudlo, Sadhvi Khanna, Rafik Fellague-Chebra, Philipp D le Coutre
BACKGROUND: Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response remains undetermined. This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib dose escalation for patients with suboptimal cytogenetic response on imatinib. METHODS: We did a phase 3, open-label, randomised trial in patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response to imatinib according to the 2009 European LeukemiaNet criteria, in Latin America, Europe, and Asia (59 hospitals and care centres in 12 countries)...
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27890072/nilotinib-against-high-dose-imatinib-for-salvage-therapy-of-chronic-myeloid-leukaemia
#18
Simona Soverini, Michele Baccarani, Giovanni Martinelli
No abstract text is available yet for this article.
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27890071/updates-on-blood-transfusion-guidelines
#19
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
December 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27843121/panobinostat-in-multiple-myeloma
#20
Morie A Gertz
No abstract text is available yet for this article.
December 2016: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"